[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer Close on the heels of a major rebranding exercise, Novo Nordisk's (NVO [https://seekingalpha.com/symbol/NVO]) CEO Mike Doustdar on Tuesday urged his employees to be more consumer-focused as the weight-loss drugmaker attempts to regain market share lost to rival Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]). "We would like to become a better and a bigger company. A company that does more for many more, both patients and consumers," s [https://www.reuters.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.
